Trial Profile

A phase III clinical trial of rapid-dissolving fluoxetine in a subpopulation of patients with autistic disorder.

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 18 Oct 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fluoxetine (Primary)
Indications Autistic disorder
Focus Registrational; Therapeutic Use

Most Recent Events

09 Oct 2012 Autism Therapeutics has had a Type C Guidance Meeting with the US FDA to discuss the completion of a phase III programme for fluoxetine rapid dissolve under Special Protocol Assessment (SPA) guidelines, according to an Autism Therapeutics media release.
02 Oct 2012 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com